India's top court to deliver Novartis judgment

Written By Unknown on Minggu, 31 Maret 2013 | 18.38

NEW DELHI — A pending Supreme Court patent decision in India could reverberate throughout the pharmaceutical industry and beyond.

India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG.

The international drug makers have been pushing for stronger patent protection in India to regulate the country's $26 billion generic drug industry, which they say often flouts intellectual property rights. They warn that a rejection of Novartis' position could discourage new research and refinement.

At issue is a legal provision in India's 2005 patent law aimed at preventing companies from getting fresh patents for minor changes to medicines — a practice known as "evergreening."

The drug in question is called Gleevec and it's used to treat leukemia and other cancers. It costs $2,600 a month while the generic version available in India costs around $175 per month.


Anda sedang membaca artikel tentang

India's top court to deliver Novartis judgment

Dengan url

http://sedangapasaja.blogspot.com/2013/03/india-top-court-to-deliver-novartis.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

India's top court to deliver Novartis judgment

namun jangan lupa untuk meletakkan link

India's top court to deliver Novartis judgment

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger